Cancer patients, advocates, and doctors are joining MSD in welcoming a milestone decision by the Federal Government to provide subsidised access to KEYTRUDA® (pembrolizumab) for over 10,000 newly eligible Australians over the next four years, with certain advanced and metastatic cancers.1 From 1 September 2026, the cost of KEYTRUDA will be subsidised through the ... Continued